| Gefitinib in Treating Patients With Cervical Cancer (NCT00049556) | National Cancer Institute (NCI) | 2002-10-01 |
| Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer (NCT00052468) | AGO Study Group | 2002-08-01 |
| PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer (NCT00085384) | M.D. Anderson Cancer Center | 2002-07-01 |
| Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT00217555) | Fred Hutchinson Cancer Center | 2002-07-01 |
| UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer (NCT00045175) | University Health Network, Toronto | 2002-06-01 |
| Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor (NCT00039585) | National Cancer Institute (NCI) | 2002-05-01 |
| Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00055614) | Beth Israel Deaconess Medical Center | 2002-05-01 |
| Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis (NCT00033605) | Alliance for Clinical Trials in Oncology | 2002-04-01 |
| Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00028912) | Memorial Sloan Kettering Cancer Center | 2001-11-01 |
| Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (NCT00028743) | NCIC Clinical Trials Group | 2001-08-31 |
| Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer (NCT00031954) | AGO Study Group | 2001-08-01 |
| Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer (NCT00032162) | AGO Study Group | 2001-08-01 |
| TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00022347) | Memorial Sloan Kettering Cancer Center | 2001-05-01 |
| S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer (NCT00008138) | SWOG Cancer Research Network | 2001-03-01 |
| ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00014690) | AstraZeneca | 2001-03-01 |
| Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00021034) | Memorial Sloan Kettering Cancer Center | 2001-03-01 |
| CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer (NCT00017017) | Memorial Sloan Kettering Cancer Center | 2001-02-01 |
| Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (NCT00550784) | City of Hope Medical Center | 2001-01-01 |
| Immunotoxin Therapy in Treating Patients With Advanced Cancer (NCT00006981) | National Cancer Institute (NCI) | 2000-12-01 |
| Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma (NCT00157560) | Massachusetts General Hospital | 2000-12-01 |
| Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer (NCT00010179) | NCIC Clinical Trials Group | 2000-10-31 |
| Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00006942) | National Cancer Institute (NCI) | 2000-10-01 |
| Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum (NCT00012090) | Memorial Sloan Kettering Cancer Center | 2000-09-01 |
| Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00006391) | NYU Langone Health | 2000-08-01 |
| Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer (NCT00005025) | John Stoddard Cancer Center at Iowa Methodist Medical Center | 2000-06-01 |
| Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer (NCT00045461) | Ludwig-Maximilians - University of Munich | 2000-06-01 |
| Specimen and Data Study for Ovarian Cancer Early Detection and Prevention (NCT00005095) | Northwestern University | 2000-03-01 |
| Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer (NCT00006041) | Memorial Sloan Kettering Cancer Center | 2000-02-01 |
| Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer (NCT00006454) | AGO Study Group | 1999-12-01 |
| Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer (NCT00003967) | Gynecologic Oncology Group | 1999-09-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |
| Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer (NCT00004934) | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | 1999-08-01 |
| Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer (NCT00004060) | Daiichi Sankyo | 1999-07-01 |
| Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors (NCT00004082) | Beth Israel Deaconess Medical Center | 1999-07-01 |
| SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084) (NCT00002960) | Merck Sharp & Dohme LLC | 1999-06-01 |
| ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment (NCT00005645) | Genzyme, a Sanofi Company | 1999-05-01 |
| Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer (NCT00003385) | Gynecologic Oncology Group | 1999-03-01 |
| Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00004012) | Memorial Sloan Kettering Cancer Center | 1998-12-01 |
| Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer (NCT00004064) | AltaRex | 1998-11-01 |
| Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer (NCT00003636) | European Organisation for Research and Treatment of Cancer - EORTC | 1998-09-01 |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00003944) | Fox Chase Cancer Center | 1998-08-01 |
| Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer (NCT00003382) | Gynecologic Oncology Group | 1998-05-01 |
| Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00003560) | Herbert Irving Comprehensive Cancer Center | 1998-05-01 |
| Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00019461) | National Cancer Institute (NCI) | 1998-04-01 |
| Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy (NCT00003634) | AltaRex | 1998-04-01 |
| Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00003358) | Memorial Sloan Kettering Cancer Center | 1998-01-01 |
| S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission (NCT00003120) | SWOG Cancer Research Network | 1997-11-01 |
| Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum (NCT00003160) | Theradex | 1997-09-01 |
| Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract (NCT00003334) | NYU Langone Health | 1997-03-01 |
| Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer (NCT00003064) | Herbert Irving Comprehensive Cancer Center | 1997-01-01 |
| Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer (NCT00002895) | Medical Research Council | 1996-06-01 |
| Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer (NCT00002600) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1994-10-21 |
| Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers (NCT00002538) | Gynecologic Oncology Group | 1993-09-01 |
| Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00006235) | Gynecologic Oncology Group | |
| Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission (NCT00693342) | Gynecologic Oncology Group | |